Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European ...
02 May 2019 - 6:05AM
Novavax Announces Presentation of Phase 3 Data from RSV Maternal
Immunization Program at 37th Annual Meeting of the European Society
for Pediatric Infectious Diseases
Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz,
M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology
and Microbiology at Baylor College of Medicine and Medical
Director, Transplant Infectious Diseases, Texas Children’s
Hospital, will present data from the company’s global Phase 3
clinical trial of ResVax™ at the 37th Annual Meeting of the
European Society for Pediatric Infectious Diseases (ESPID) in
Ljubljana, Slovenia, being held May 6-11, 2019. ResVax is Novavax’
respiratory syncytial virus (RSV) fusion (F) protein recombinant
nanoparticle vaccine.
Details are as follows:
Abstract title: |
|
|
Phase 3 PREPARE study: efficacy and safety of an RSV
vaccine administered to pregnant women |
Session title: |
|
|
PIDS/ESPID Joint Plenary Symposium – The future of
vaccines (is now) |
Session code and track: |
|
|
ST01; Science track |
Location: |
|
|
Kocka Hall |
Date: |
|
|
Tuesday, May 7 |
Time: |
|
|
10:30 a.m. ET |
The abstract for the presentation can be found
here. In addition, the presentation will be live streamed. For more
information, please visit the ESPID meeting’s website.
About ResVax™ and the Prepare
Trial
ResVax is an RSV fusion (F) protein recombinant
nanoparticle vaccine with aluminum phosphate as an adjuvant. It is
being developed to protect infants from RSV disease via maternal
immunization, which may offer the best method of protection from
RSV disease in infants through the first months of life. In
February 2019, Novavax announced top-line data from Prepare™, a
global Phase 3 clinical trial in 4,636 pregnant women, at least
3,000 of whom have received the vaccine, and their infants. Prepare
is supported by an $89.1 million grant from the Bill & Melinda
Gates Foundation (BMGF).
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that drives improved health globally through
the discovery, development, and commercialization of innovative
vaccines to prevent serious infectious diseases. Its two priority
programs are ResVax™, its RSV vaccine for infants via maternal
immunization, and NanoFlu™, its quadrivalent influenza nanoparticle
vaccine. Novavax’ proprietary recombinant technology platform
combines the power and speed of genetic engineering to efficiently
produce a new class of highly immunogenic nanoparticles addressing
urgent global health needs.
For more information, visit
www.novavax.com and connect with us on Twitter and
LinkedIn.
Contacts:
InvestorsNovavax, Inc.Erika Trahanir@novavax.com240-268-2000
WestwickeJohn
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownAndrea
Cohenandreacohen@sambrown.com917-209-7163
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024